Post on 03-Apr-2022
transcript
Department of Pathology and Laboratory Medicine – Reference Ranges
Hospital of the University of Pennsylvania
Department of Pathology and Laboratory Medicine
3400 Spruce Street
Philadelphia, PA 19104
Reference Ranges Oct. 2018 – Oct. 2019
Title: Assay Reference Ranges and/or Interpretive Comments
analyte Alpha fetoprotein, AFP
Beta 2 Microglobulin, BMGCA125
CA15-3CA19-9
CEAC-peptide
Females Males(Age yrs.) (Age yrs.)
18-21 51-321 18-21 24-53721-30 18-391 21-30 85-69031-40 23-266 31-40 106-46441-50 19-231 41-50 70-49551-60 8-188 51-60 38-31361-70 12-133 61-70 24-244≥ 71 7-177 ≥ 71 5-253
Males <15 - 31.5 pg/mLFemales
Early Follicular 22.4 – 115 pg/mLMid-Follicular Phase 25-115 pg/mL
Ovulatory Peak 32.1 – 517 pg/mLMid Luteal Phase 36.5 – 246 pg/mLPost-Menopausal <25.1 pg/mL
Erythropoetin, EPOMales 1.27 – 19.26 mIU/mLFemales
Mid-Follicular Phase 3.85 – 8.78 mIU/mLMid-Cycle Peak 4.54 – 22.51 mIU/mL
Mid-Luteal Phase 1.79 – 5.12 mIU/mLPost-Menopausal 16.74 – 113.59 mIU/mL
Growth Hormone
Hemoglobin A1c
HCG, Oncology Homocysteine
Total IgE< 0.1 kU/L Not Detectable
0.1 – 0.34 kU/LVery Low (Clinical relevance indeterminate)
0.35 – 0.70 kU/L Low0.71 – 3.50 kU/L Moderate
3.51 – 17.50 kU/L High>17.5 kU/L Very High
Insulin
The level of growth hormone in serum is subject to wide and sometimes rapid fluctuations during the day, and may be altered
greatly by normal physiological events. Therefore, results obtained from a single random specimen are difficult to interpret and challenge
tests may be required to establish a diagnosis.
Male: <5 mIU/mL Female, Non-Pregnant: <5 mIU/mL
1.1-2.4 mg/L0 - 35 U/mL0 - 25 U/mL0 - 35 U/mL
0 - 4.7 ng/mL
Interp comments
Effective date: 10/16/2018Prepared By: Nichole Rulander
µg/dL
Estradiol, E2
Follicle Stimulating Hormone, FSH
4.0 - 5.6 %
4-12 µmol/L2 – 214 kU/L
2.6- 24.9 mIU/L
reference ranges
Allergen Specific IgE <=0.34 kU/L
Patients with an AMH concentration < 0.7 ng/mL frequently have < 3 antral follicles. Women with serum AMH > 2.0 ng/mL may benefit from
decreased ovarian stimulation dosing to avoid hyperstimulation. Women with polycystic ovarian syndrome have approximately 3-fold
elevated results (median: 7 ng/mL, 5th percentile: 3 ng/mL)
3 - 19 mIU/mL
1.1 - 4.4 ng/mL
DHEA-S
µg/dL
Hospital of the University of PennsylvaniaDepartment of Pathology and Laboratory
Section: ENDOCRINOLOGY
Anti- Mullerian Hormone, AMH
Females, Age yrs.
25 - 2930 - 3435 - 3940 - 44
0.89 - 9.85 ng/mL0.58 - 8.13 ng/mL0.15 - 7.49 ng/mL0.03 - 5.47 ng/mL
20 - 24 1.22 - 11.7 ng/mL
0 -5 IU/mL
Males 1.24 – 8.62 mIU/mLFemales
Mid-Follicular Phase 2.12-10.89 mIU/mLMid-Cycle Peak 19.18-103.03 mIU/mL
Mid-Luteal Phase 1.20-12.86 mIU/mLPost Menopausal 10.87-58.64 mIU/mL
Progesterone
Males 2.64 - 13.13 ng/mLFemales
pre-menopausal (<50 years of age)
3.34-26.72 ng/mL
post-menopausal (≥50 years of age)
2.74-19.64 ng/mL
Parathyroid Hormone, PTH
TestosteroneThyroglobulin
Thyroglobulin-AbTPO-Ab
Tryptase HIV Ag/Ab
HCVHepatitis B Surface Ag
Hepatitis B Surface antibody Hepatitis B CORE antibody
Hepatitis B CORE-IgMHepA-IgG
HepA-IgM
Adult Males 20 - 49 years: 249 - 836 ng/dL
Adult Males >50 years: 193 - 740 ng/dL
1.6-6.9 pmol/L
1.59 - 50.0 ng/mL≤3.9 U/mL
Adult Female (>17 yrs): Follicular Phase: <0.8 - 1.1 ng/mL
Midcycle: <0.8-1.7 ng/mL Luteal phase: 0.9 - 21.0 ng/mL
Oral contraceptives: <0.8-1.0 ng/mL Postmenopause: <0.8-1.0 ng/mL
Ist trimester pregnancy: 9.3 - 33.2 ng/mL 2nd trimester pregnancy: 29.5 - 50.0 ng/mL 3rd trimester pregnancy: 83.1 - 160.0 ng/mL
Adult Male (>17 yrs): <0.8 - 0.9 ng/mL
Prolactin
Luteinizing Hormone, LH
≤8.9 U/mL
Qualitative, no reference ranges
≤8.9 U/mL
THERAPEUTIC RANGES page 1 of 2
HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA
DIVISION OF LABORATORY MEDICINE
TOXICOLOGY LABORATORY
TEST THERAPEUTIC RANGE CRITICAL VALUE
Amikacin Trough Less than 8 mg/L Trough: >10 mg/L
Peak (1) Patients on once-daily dosing: 40 - 60 mg/L Peak: >30 mg/L
(2) Patients on traditional dosing: 20 - 30 mg/L
Cyclosporine Kidney Transplants >500 mcg/L
100-250 mcg/L, first three months post transplant.
80-125 mcg/L, after three months post transplant.
Heart Transplants
200-300 mcg/L, first twelve months post transplant.
100-150 mcg/L, after first year post transplant.
Liver Transplants
200-300 mcg/L.
Lung Transplants
250-350 mcg/L, first twelve months post transplant.
200-300 mcg/L, after first year post transplant.
Bone Marrow Transplants
200-250 mcg/L.
Ethanol None detected. >80 mg/dL
Everolimus 3.0 - 8.0 ng/mL
Isopropanol None detected. >50 mg/dL
Lamotrigine 2.5 - 15 mg/L
Levetiracetam (Keppra) 12 - 46 mg/L
Lidocaine 1.5-5.0 mg/L >5 mg/L
Methanol None detected. >10 mg/dL
Methotrexate The therapeutic range for methotrexate is protocol dependent. For specimens
obtained 48 hours after initiation of a methotrexate infusion, the range is
0.05 to 0.10 umole/L.
MPA (mycophenolic acid) 1.0 - 3.5 mg/L (following an overnight fast)
Phenytoin, Free 1.0 - 2.0 mg/L
Rapamycin 4.0--12.0 ng/mL
THERAPEUTIC RANGES page 2 of 2
HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA
DEPARTMENT OF LABORATORY MEDICINE
TOXICOLOGY LABORATORY
TEST THERAPEUTIC RANGE CRITICAL VALUE
Tacrolimus Renal transplant patients > 20 ug/L
(FK506) 0-3 months, 8-10 ug/L
4-6 months, 6-8 ug/L
6-12 months, 5-7 ug/L
> 12 months, 4-6 ug/L
Heart transplant patients
0-3 months, 10-12 ug/L > 20 ug/L
3-6 months, 10 ug/L
6-12 months, 8-10 ug/L
> 12 months, 5-8 ug/L
Liver transplant patients
1st week, 10-20 ug/L
1-4 weeks, 5-15 ug/L
> 4 weeks, 5-10 ug/L
Lung transplant patients
0-12 months, 8-12 ug/L
>12 months, 6-8 ug/L
Bone marrow transplant patients
5-15 ug/L
Topiramate 5 - 20 mg/L
Vitamin D, 25-hydroxy, Total 25 - 80 ng/mL
Zonisamide 10 - 40 mg/L
_______________________
Dr. Leslie Shaw
9/7/2018
Hemoglobin ID Normal Reference Ranges
Hgb A 95 – 98% Hgb A2 1.5 - 3.5% Hgb F 0 – 1% MCV 80 – 100 fl Hgb (Females) 12.0 – 16.0 g/dL Hgb (Males) 13.5 – 17.0 g/dL
Bone Marrow Diff Blasts BM 0-4% Promyelo BM 0-8% Meta/Myelo BM 18-41% Segs/Bands BM 7-32% Monocyte BM 0-2% Eos BM 0-4% Basophil BM 0-1% Lymph BM 5-20% Plasma Cell BM 0-3% NRBC BM 8-35%
Penn Medicine
Hospital of the University of Pennsylvania
Department of Pathology and Laboratory Medicine
Division of Laboratory Medicine
Section: Point of Care Testing
Page 1 of 6
Version: 1.0
Title: Point of Care Reference Ranges Effective: 5/26/20166/7/2016
Modified: 9/21/2017
Print Status: Uncontrolled When Printed
AccuChek Inform II Units Whole blood glucose 70-99 mg/dL Abbott i-STAT Troponin I 0.00-0.08 ng/mL DCA Vantage Hemoglobin A1C 4.0%-6.0%
Hemochron Signature Elite
Prothrombin Time 10.7-13.8 Seconds
INR 0.9-1.1
Prothrombin Time/INR: Result of the Prothrombin time is reported in seconds and is converted to the international normalized ratio (INR). The INR is a calculation based on the result of the prothrombin time and serves to standardize results from different laboratories and the variable response to different thromboplastin reagents. Recommended therapeutic warfarin range is patient specific and is determined by the physician/provider
Activated Clotting Time Ranges are established by the testing unit and the procedure that is being performed.
Radiometer ABL 90 Flex
Blood Gas
Test Age Arterial Units
pH 0 to 2D 7.29 to 7.45
Reference Sheets page 2 of 6
POCT Reference Ranges 2017 6/7/2016
Print Status: Uncontrolled When Printed
2D to 1M 7.31 to 7.45
1M to 2Y 7.34 to 7.44
2Y to 19Y 7.37 to 7.44
>19 Y 7.35 to 7.45
pCO2 0 to 1W 27 to 40 mmHg
1W to 1M 30 to 42 mmHg
1M to 2Y 30 to 44 mmHg
2Y to 19Y 31 to 47 mmHg
19Y to 21Y 34 to 48 mmHg
>21Y 34 to 45 mmHg
pO2 0 to 1W 54 to 95 mmHg
1W to 1M 65 to 98 mmHg
1M to 2Y 80 to 105 mmHg
2Y to 19Y 83 to 108 mmHg
19Y to 21Y 87 to 112 mmHg
>21Y 75 to 100 mmHg
HCO3 0 to 1W 16 to 22 mmol/L
1W to 1M 18 to 24 mmol/L
1M to 2Y 18 to 25 mmol/L
2Y to 19Y 20 to 26 mmol/L
Reference Sheets page 3 of 6
POCT Reference Ranges 2017 6/7/2016
Print Status: Uncontrolled When Printed
19Y to 21Y 22 to 27 mmol/L
>21Y 22 to 26 mmol/L
Sodium-Na+ 0 - 1M 132 to 145 mmol/L
1M - 1Y 134 to 144 mmol/L
>1Y 133 to 143 mmol/L
Potassium-K+ 0 - 1Y 4.0 to 6.2 mmol/L
>1Y 3.5 to 5.3 mmol/L
Chloride O minute to 1 month 98-106 mmol/L
> 1 month 96 -110 mmol/L
Hematocrit 0-1D 42-60 %
1D-1M 45-65 %
1M-3M 31-55 %
3M-6M 29-41 %
6M-150y Male 42 to 51 %
6M-150y Female 33 to 45 %
Hemoglobin 0-1D 13.5 to 19.5 g/dL
1D-1M 14.5 to 22.0 g/dL
1M-3M 10.0 to 18.0 g/dL
3M-6M 9.5 to 13.5 g/dL
6M-150y Male 13.5 to 17.5 g/dL
Reference Sheets page 4 of 6
POCT Reference Ranges 2017 6/7/2016
Print Status: Uncontrolled When Printed
6M-150y Female 12.0 to 16.0 g/dL
Glucose 0 – 1Y 70-99 mg/dL
>1Y 70-99 mg/dL
Ionized Calcium
1.00 to 1.25 mmol/L
Lactate 0.5-1.6 mmol/L
sO2 94.0-99.0 %
O2Hgb > 1month 94.0-99.0 %
O2 content 16 - 23 mL/dL
COHgb 0.5-1.5 %
(interpretive comment: "Chronic heavy smokers may have levels up to 10%.")
MetHgb 0-1.4 %
Base Excess (-3) - (+3)
Test Age Venous Units
pH 7.31 to 7.41
pO2 30 to 45 mmHg
pCO2 40 to 50 mmHg
Lactate 0.5-2.2 mmol/L
HCO3 0 – 2Y 22 to 29 mmol/L
Reference Sheets page 5 of 6
POCT Reference Ranges 2017 6/7/2016
Print Status: Uncontrolled When Printed
>2Y 22 to 29 mmol/L
Sodium-Na+ 0 - 1M 132 to 145 mmol/L
1M - 1Y 134 to 144 mmol/L
>1Y 133 to 143 mmol/L
Potassium-K+ 0 to 1Y 4.0 to 6.2 mmol/L
>1Y 3.5 to 5.3 mmol/L
Chloride O minute to 1 month 98-106 mmol/L
> 1 month 96 -110 mmol/L
Ionized Calcium
1.00 to 1.25 mmol/L
sO2 70-80 %
O2Hgb 40-85 %
COHgb 0.5-1.5 %
(interpretive comment: "Chronic heavy smokers may have levels up to 10%.")
MetHgb 0-1.4% %
Glucose 0 – 1Y 70-99 mg/dL
>1Y 70-99 mg/dL
Base Excess -3 to +3 mg/dL
Hematocrit 0-1D 42-60 %
1D-1M 45-65 %
Reference Sheets page 6 of 6
POCT Reference Ranges 2017 6/7/2016
Print Status: Uncontrolled When Printed
1M-3M 31-55 %
3M-6M 29-41 %
6M-150y Male 42 to 51 %
6M-150y Female 33 to 45 %
Hemoglobin 0-1D 13.5 to 19.5 g/dL
1D-1M 14.5 to 22.0 g/dL
1M-3M 10.0 to 18.0 g/dL
3M-6M 9.5 to 13.5 g/dL
6M-150y Male 13.5 to 17.5 g/dL
6M-150y Female 12.0 to 16.0 g/dL